Leveraging a unique dataset with matched biopsies before and after AR inhibition with enza treatment, we identified enriched immune cell signaling pathways and IFNγ signaling activity in the patients’ on-treatment tumor samples that showed AR deactivation. Here, AR is linked to neoplasm.